191 related articles for article (PubMed ID: 33534636)
21. Phosphorothioate modified oligonucleotide-protein interactions.
Crooke ST; Vickers TA; Liang XH
Nucleic Acids Res; 2020 Jun; 48(10):5235-5253. PubMed ID: 32356888
[TBL] [Abstract][Full Text] [Related]
22. Acute hepatotoxicity of 2' fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins.
Shen W; De Hoyos CL; Sun H; Vickers TA; Liang XH; Crooke ST
Nucleic Acids Res; 2018 Mar; 46(5):2204-2217. PubMed ID: 29390093
[TBL] [Abstract][Full Text] [Related]
23. Systematic Analysis of Chemical Modifications of Phosphorothioate Antisense Oligonucleotides that Modulate Their Innate Immune Response.
Pollak AJ; Zhao L; Crooke ST
Nucleic Acid Ther; 2023 Apr; 33(2):95-107. PubMed ID: 36749166
[TBL] [Abstract][Full Text] [Related]
24. Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides.
Wang S; Sun H; Tanowitz M; Liang XH; Crooke ST
Nucleic Acids Res; 2017 May; 45(9):5309-5322. PubMed ID: 28379543
[TBL] [Abstract][Full Text] [Related]
25. SIDT2 Inhibits Phosphorothioate Antisense Oligonucleotide Activity by Regulating Cellular Localization of Lysosomes.
Zhao JC; Saleh A; Crooke ST
Nucleic Acid Ther; 2023 Apr; 33(2):108-116. PubMed ID: 36576400
[TBL] [Abstract][Full Text] [Related]
26. β-1,3-Glucan/antisense oligonucleotide complex stabilized with phosphorothioation and its gene suppression.
Mochizuki S; Sakurai K
Bioorg Chem; 2010 Dec; 38(6):260-4. PubMed ID: 20673953
[TBL] [Abstract][Full Text] [Related]
27. COPII vesicles can affect the activity of antisense oligonucleotides by facilitating the release of oligonucleotides from endocytic pathways.
Liang XH; Sun H; Nichols JG; Allen N; Wang S; Vickers TA; Shen W; Hsu CW; Crooke ST
Nucleic Acids Res; 2018 Nov; 46(19):10225-10245. PubMed ID: 30239896
[TBL] [Abstract][Full Text] [Related]
28. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus.
Liang XH; Sun H; Nichols JG; Crooke ST
Mol Ther; 2017 Sep; 25(9):2075-2092. PubMed ID: 28663102
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and cellular activity of stereochemically-pure 2'-O-(2-methoxyethyl)-phosphorothioate oligonucleotides.
Li M; Lightfoot HL; Halloy F; Malinowska AL; Berk C; Behera A; Schümperli D; Hall J
Chem Commun (Camb); 2017 Jan; 53(3):541-544. PubMed ID: 27966701
[TBL] [Abstract][Full Text] [Related]
30. Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor.
Schmidt K; Prakash TP; Donner AJ; Kinberger GA; Gaus HJ; Low A; Østergaard ME; Bell M; Swayze EE; Seth PP
Nucleic Acids Res; 2017 Mar; 45(5):2294-2306. PubMed ID: 28158620
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages.
Wan WB; Migawa MT; Vasquez G; Murray HM; Nichols JG; Gaus H; Berdeja A; Lee S; Hart CE; Lima WF; Swayze EE; Seth PP
Nucleic Acids Res; 2014 Dec; 42(22):13456-68. PubMed ID: 25398895
[TBL] [Abstract][Full Text] [Related]
32. Origins of the Increased Affinity of Phosphorothioate-Modified Therapeutic Nucleic Acids for Proteins.
Hyjek-Składanowska M; Vickers TA; Napiórkowska A; Anderson BA; Tanowitz M; Crooke ST; Liang XH; Seth PP; Nowotny M
J Am Chem Soc; 2020 Apr; 142(16):7456-7468. PubMed ID: 32202774
[TBL] [Abstract][Full Text] [Related]
33. Insights into innate immune activation via PS-ASO-protein-TLR9 interactions.
Pollak AJ; Zhao L; Vickers TA; Huggins IJ; Liang XH; Crooke ST
Nucleic Acids Res; 2022 Aug; 50(14):8107-8126. PubMed ID: 35848907
[TBL] [Abstract][Full Text] [Related]
34. Integrated Assessment of the Clinical Performance of GalNAc
Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
[TBL] [Abstract][Full Text] [Related]
35. Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging.
Mukherjee P; Aksamitiene E; Alex A; Shi J; Bera K; Zhang C; Spillman DR; Marjanovic M; Fazio M; Seth PP; Frazier K; Hood SR; Boppart SA
Nucleic Acid Ther; 2022 Jun; 32(3):163-176. PubMed ID: 34797690
[TBL] [Abstract][Full Text] [Related]
36. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides.
Iwamoto N; Butler DCD; Svrzikapa N; Mohapatra S; Zlatev I; Sah DWY; Meena ; Standley SM; Lu G; Apponi LH; Frank-Kamenetsky M; Zhang JJ; Vargeese C; Verdine GL
Nat Biotechnol; 2017 Sep; 35(9):845-851. PubMed ID: 28829437
[TBL] [Abstract][Full Text] [Related]
37. Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.
Hvam ML; Cai Y; Dagnæs-Hansen F; Nielsen JS; Wengel J; Kjems J; Howard KA
Mol Ther; 2017 Jul; 25(7):1710-1717. PubMed ID: 28641935
[TBL] [Abstract][Full Text] [Related]
38. Endosomal Escape of Antisense Oligonucleotides Internalized by Stabilin Receptors Is Regulated by Rab5C and EEA1 During Endosomal Maturation.
Miller CM; Wan WB; Seth PP; Harris EN
Nucleic Acid Ther; 2018 Apr; 28(2):86-96. PubMed ID: 29437530
[TBL] [Abstract][Full Text] [Related]
39. In vitro metabolism of 2'-ribose unmodified and modified phosphorothioate oligonucleotide therapeutics using liquid chromatography mass spectrometry.
Kim J; El Zahar NM; Bartlett MG
Biomed Chromatogr; 2020 Jul; 34(7):e4839. PubMed ID: 32246854
[TBL] [Abstract][Full Text] [Related]
40. Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies.
Lorenz P; Baker BF; Bennett CF; Spector DL
Mol Biol Cell; 1998 May; 9(5):1007-23. PubMed ID: 9571236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
